- Home
- EDSA vs SNGX Comparison
EDSA vs SNGX Comparison
Compare EDSA & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDSA
- SNGX
- Stock Information
- Founded
- EDSA 2015
- SNGX 1987
- Country
- EDSA Canada
- SNGX United States
- Employees
- EDSA N/A
- SNGX N/A
- Industry
- EDSA Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- EDSA Health Care
- SNGX Health Care
- Exchange
- EDSA Nasdaq
- SNGX Nasdaq
- Market Cap
- EDSA 6.2M
- SNGX 6.5M
- IPO Year
- EDSA N/A
- SNGX 1987
- Fundamental
- Price
- EDSA $1.96
- SNGX $1.89
- Analyst Decision
- EDSA Strong Buy
- SNGX
- Analyst Count
- EDSA 1
- SNGX 0
- Target Price
- EDSA $21.00
- SNGX N/A
- AVG Volume (30 Days)
- EDSA 34.1K
- SNGX 18.7K
- Earning Date
- EDSA 05-14-2025
- SNGX 05-09-2025
- Dividend Yield
- EDSA N/A
- SNGX N/A
- EPS Growth
- EDSA N/A
- SNGX N/A
- EPS
- EDSA N/A
- SNGX N/A
- Revenue
- EDSA N/A
- SNGX $2,342.00
- Revenue This Year
- EDSA N/A
- SNGX N/A
- Revenue Next Year
- EDSA N/A
- SNGX N/A
- P/E Ratio
- EDSA N/A
- SNGX N/A
- Revenue Growth
- EDSA N/A
- SNGX N/A
- 52 Week Low
- EDSA $1.55
- SNGX $1.68
- 52 Week High
- EDSA $5.59
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- EDSA 35.93
- SNGX 45.39
- Support Level
- EDSA $1.96
- SNGX $1.85
- Resistance Level
- EDSA $2.06
- SNGX $1.95
- Average True Range (ATR)
- EDSA 0.10
- SNGX 0.09
- MACD
- EDSA -0.00
- SNGX 0.01
- Stochastic Oscillator
- EDSA 30.77
- SNGX 42.11
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).